Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Studie van gerichte therapieën voor de behandeling van volwassen deelnemers met actieve psoriatica -artritis

5 november 2026 bijgewerkt door: AbbVie

Een fase 2 multicenter, gerandomiseerde, platformstudie van gerichte therapieën voor de behandeling van volwassen proefpersonen met actieve psoriatica -artritis

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.

The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

300

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Quebec
      • Sherbrooke, Quebec, Canada, J1G 2E8
        • Werving
        • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
      • Trois-Rivières, Quebec, Canada, G9A 3X2
        • Werving
        • Centre de Recherche Musculo-Squelettique /ID# 274397
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7H 0P4
        • Werving
        • Dr. Latha Naik Medical Professional Corporation /ID# 272803
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Frankrijk, 06001
        • Werving
        • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
    • Auvergne-Rhône-Alpes
      • Caluire-et-Cuire, Auvergne-Rhône-Alpes, Frankrijk, 69300
        • Werving
        • Infirmerie Protestante De Lyon /ID# 273731
    • Indre-et-Loire
      • Chambray-lès-Tours, Indre-et-Loire, Frankrijk, 37170
        • Werving
        • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
    • Loiret
      • Orléans, Loiret, Frankrijk, 45067
        • Voltooid
        • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrijk, 33076
        • Voltooid
        • Chu Bordeaux - Hopital Pellegrin /ID# 273390
      • Budapest, Hongarije, 1027
        • Werving
        • Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
      • Budapest, Hongarije, 1023
        • Werving
        • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
    • Borsod-Abauj Zemplen county
      • Miskolc, Borsod-Abauj Zemplen county, Hongarije, 3529
        • Werving
        • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
    • Fejér
      • Székesfehérvár, Fejér, Hongarije, 8000
        • Werving
        • Complex Rendelo Med Zrt. /ID# 272570
      • Veszprém, Fejér, Hongarije, 8200
        • Werving
        • Vital-Medicina /ID# 272855
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-068
        • Werving
        • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
    • Masovian Voivodeship
      • Pruszków, Masovian Voivodeship, Polen, 05-800
        • Werving
        • MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
      • Warsaw, Masovian Voivodeship, Polen, 02-665
        • Werving
        • Centrum Medyczne Reuma Park /ID# 273301
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polen, 15-351
        • Voltooid
        • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
    • Warmian-Masurian Voivodeship
      • Elblag, Warmian-Masurian Voivodeship, Polen, 82-300
        • Voltooid
        • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
      • Uherské Hradiště, Tsjechië, 686 01
        • Werving
        • Medical Plus Research /ID# 272363
      • Zlín, Tsjechië, 760 01
        • Werving
        • PV Medical Services /ID# 272368
    • Brno-mesto
      • Brno, Brno-mesto, Tsjechië, 638 00
        • Werving
        • Revmatologie /ID# 272367
    • Moravian-Silesian Region
      • Hlučín, Moravian-Silesian Region, Tsjechië, 748 01
        • Werving
        • L.K.N. Arthrocentrum /ID# 272366
    • California
      • Huntington Beach, California, Verenigde Staten, 92648-5994
        • Werving
        • Newport Huntington Medical Group /ID# 272764
        • Contact:
          • Site Coordinator
          • Telefoonnummer: 714-923-7112
    • Florida
      • Avon Park, Florida, Verenigde Staten, 33825
        • Werving
        • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
        • Contact:
          • Site Coordinator
          • Telefoonnummer: 863-314-8555
      • Clearwater, Florida, Verenigde Staten, 33765
        • Werving
        • Clinical Research Of West Florida - Phase I Unit /ID# 273198
      • Orlando, Florida, Verenigde Staten, 32819
        • Werving
        • HMD Research LLC /ID# 273086
      • Tamarac, Florida, Verenigde Staten, 33321
        • Werving
        • West Broward Rheumatology Associates /ID# 272892
      • Tampa, Florida, Verenigde Staten, 33606
        • Werving
        • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
        • Contact:
          • Site Coordinator
          • Telefoonnummer: (813) 870-1292
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
      • Skokie, Illinois, Verenigde Staten, 60076
        • Voltooid
        • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
      • Willowbrook, Illinois, Verenigde Staten, 60527
        • Werving
        • Willow Rheumatology and Wellness /ID# 277354
    • Maryland
      • Cumberland, Maryland, Verenigde Staten, 21502
        • Voltooid
        • Klein & Associates /ID# 272829
    • New Hampshire
      • Lebanon, New Hampshire, Verenigde Staten, 03756
        • Werving
        • Dartmouth-Hitchcock Medical Center /ID# 272702
        • Contact:
          • Site Coordinator
          • Telefoonnummer: 603-650-4717
    • Ohio
      • Middleburg Heights, Ohio, Verenigde Staten, 44130
        • Werving
        • Paramount Medical Research and Consulting /ID# 272757
    • Pennsylvania
      • Duncansville, Pennsylvania, Verenigde Staten, 16635
        • Werving
        • Altoona Center For Clinical Research /ID# 272593
        • Contact:
          • Site Coordinator
          • Telefoonnummer: 814-296-6108
    • Tennessee
      • Memphis, Tennessee, Verenigde Staten, 38119
        • Werving
        • Private Practice - Dr. Ramesh C. Gupta /ID# 272897
    • Texas
      • Austin, Texas, Verenigde Staten, 78745
        • Werving
        • Tekton Research - West Gate /ID# 272765
      • Frisco, Texas, Verenigde Staten, 75035
        • Werving
        • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
      • Houston, Texas, Verenigde Staten, 77089-6142
        • Werving
        • Accurate Clinical Research - Houston /ID# 272754
      • San Antonio, Texas, Verenigde Staten, 78251
        • Werving
        • Tekton Research, LLC /ID# 272901
      • Tomball, Texas, Verenigde Staten, 77375
        • Werving
        • DM Clinical Research - Tomball /ID# 272760

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
  • Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
  • Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
  • Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
  • Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria:

  • Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
  • Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
  • Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Substudy 1: Risankizumab Monotherapy

Participants will receive risankizumab

Subcutaneous (SC) Injection

Experimenteel: Substudy 1: Lutikizumab Monotherapy

Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week.

Subcutaneous (SC) Injection

Experimenteel: Substudy 1: Lutikizumab and Risankizumab Combination Therapy

Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

Experimenteel: Substudy 2: ABBV-701 Monotherapy

Participants will initially receive ABBV-701.

Subcutaneous (SC) Injection

Experimenteel: Substudy 2: Risankizumab Monotherapy

Participants will receive risankizumab.

Subcutaneous (SC) Injection

Experimenteel: Substudy 2: ABBV-701 and Risankizumab Combination Therapy

Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

Experimenteel: Substudy 3: ABBV-547 Dose A

Participants will receive ABBV-547 Dose A.

Subcutaneous (SC) Injection

Experimenteel: Substudy 3: ABBV-547 Dose B

Participants will receive ABBV-547 Dose B.

Subcutaneous (SC) Injection

Experimenteel: Substudy 3: ABBV-547 Dose C

Participants will receive ABBV-547 Dose C.

Subcutaneous (SC) Injection

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Tijdsspanne: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

  1. ≥ 50% improvement in 68-tender joint count;

  2. ≥ 50% improvement in 66-swollen joint count; and

  3. ≥ 50% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Number of Participants With Adverse Events (AEs)
Tijdsspanne: Up to Week 52

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to Week 52

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Tijdsspanne: At Week 16

A participant was classified as achieving MDA if 5 of the following 7 criteria were met:

  • Tender joint count (out of 68 joints) ≤ 1
  • Swollen joint count (out of 66 joints) ≤ 1
  • PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3%
  • Participant's assessment of pain ≤ 1.5 (NRS from 0 to 10)
  • Participant's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10)
  • HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3)
  • Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
At Week 16
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Tijdsspanne: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

  1. ≥ 20% improvement in 68-tender joint count;

  2. ≥ 20% improvement in 66-swollen joint count; and

  3. ≥ 20% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Tijdsspanne: At Week 16

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:

  1. ≥ 70% improvement in 68-tender joint count;

  2. ≥ 70% improvement in 66-swollen joint count; and

  3. ≥ 70% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Tijdsspanne: At Week 16

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked).

The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

At Week 16

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: ABBVIE INC., AbbVie

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

11 april 2025

Primaire voltooiing (Geschat)

1 augustus 2029

Studie voltooiing (Geschat)

1 augustus 2029

Studieregistratiedata

Eerst ingediend

4 maart 2025

Eerst ingediend dat voldeed aan de QC-criteria

4 maart 2025

Eerst geplaatst (Werkelijk)

7 maart 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • M25-191
  • 2024-519291-11 (Substudy 1) (Andere identificatie: EU CT)
  • 2026-525937-21 (Substudy 2) (Andere identificatie: EU CT)
  • 2026-527719-41 (Substudy 3) (Andere identificatie: EU CT)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-tijdsbestek voor delen

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD-toegangscriteria voor delen

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren